| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
|
N Engl J Med
|
2014
|
10.10
|
|
2
|
Interleukin-2 and regulatory T cells in graft-versus-host disease.
|
N Engl J Med
|
2011
|
6.02
|
|
3
|
Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases.
|
Ann Intern Med
|
2014
|
3.24
|
|
4
|
Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation.
|
Blood
|
2011
|
2.41
|
|
5
|
Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation.
|
J Infect Dis
|
2013
|
2.17
|
|
6
|
Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
2.11
|
|
7
|
Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.
|
Sci Transl Med
|
2013
|
2.03
|
|
8
|
Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis.
|
Blood
|
2010
|
1.88
|
|
9
|
Prediction of veno-occlusive disease using biomarkers of endothelial injury.
|
Biol Blood Marrow Transplant
|
2010
|
1.76
|
|
10
|
Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation.
|
Blood
|
2013
|
1.72
|
|
11
|
Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.
|
Blood
|
2008
|
1.71
|
|
12
|
Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation.
|
J Clin Oncol
|
2012
|
1.68
|
|
13
|
Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
|
Lancet Oncol
|
2011
|
1.66
|
|
14
|
Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
|
Biol Blood Marrow Transplant
|
2011
|
1.62
|
|
15
|
Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.
|
Clin Cancer Res
|
2011
|
1.46
|
|
16
|
Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant.
|
Leuk Lymphoma
|
2012
|
1.45
|
|
17
|
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age.
|
Biol Blood Marrow Transplant
|
2010
|
1.39
|
|
18
|
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.
|
J Clin Invest
|
2013
|
1.30
|
|
19
|
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?
|
Blood
|
2012
|
1.23
|
|
20
|
Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2010
|
1.22
|
|
21
|
Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts.
|
Biol Blood Marrow Transplant
|
2011
|
1.19
|
|
22
|
Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.
|
Blood
|
2013
|
1.14
|
|
23
|
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors.
|
Blood
|
2009
|
1.12
|
|
24
|
Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
1.10
|
|
25
|
Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis.
|
Biol Blood Marrow Transplant
|
2012
|
1.10
|
|
26
|
Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
|
Biol Blood Marrow Transplant
|
2013
|
1.08
|
|
27
|
Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2013
|
1.06
|
|
28
|
The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
1.06
|
|
29
|
Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
|
Biol Blood Marrow Transplant
|
2013
|
0.96
|
|
30
|
Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients.
|
Biol Blood Marrow Transplant
|
2010
|
0.92
|
|
31
|
Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma.
|
Cancer
|
2014
|
0.91
|
|
32
|
Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
0.90
|
|
33
|
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.
|
Cancer Cell
|
2016
|
0.87
|
|
34
|
Crizotinib as salvage and maintenance with allogeneic stem cell transplantation for refractory anaplastic large cell lymphoma.
|
J Natl Compr Canc Netw
|
2014
|
0.84
|
|
35
|
Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma.
|
Haematologica
|
2012
|
0.83
|
|
36
|
Safety of posaconazole and sirolimus coadministration in allogeneic hematopoietic stem cell transplants.
|
Biol Blood Marrow Transplant
|
2012
|
0.82
|
|
37
|
White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome.
|
Am J Hematol
|
2014
|
0.79
|
|
38
|
Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome.
|
Biol Blood Marrow Transplant
|
2010
|
0.79
|
|
39
|
Sonographic features of pectoralis muscle necrosis secondary to gemcitabine-induced radiation recall: case report and review of current literature.
|
J Ultrasound Med
|
2010
|
0.78
|
|
40
|
Clinical endpoints in allogeneic hematopoietic stem cell transplantation studies: the cost of freedom.
|
Biol Blood Marrow Transplant
|
2013
|
0.76
|
|
41
|
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
|
Haematologica
|
2013
|
0.76
|
|
42
|
Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2013
|
0.75
|
|
43
|
Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma.
|
Leuk Lymphoma
|
2014
|
0.75
|